Switching immunosuppression from cyclosporine to tacrolimus in kidney transplant recipients based on CYP3A5 genotyping
X Wang, Y Yang, Z Liu, C Xiao, L Gao… - Therapeutic Drug …, 2019 - journals.lww.com
Background: Kidney transplant recipients on long-term cyclosporine (CsA) therapy may
develop multiple adverse drug events, and immunosuppression conversion from CsA to …
develop multiple adverse drug events, and immunosuppression conversion from CsA to …
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation
S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
ASR Zaltzman, LA Glick, JS Zaltzman, M Nash… - Transplantation …, 2016 - Springer
Background Tacrolimus is available as twice-daily Prograf®(Tac-BID) and the once-daily
formulation, Advagraf®(Tac-OD). Although therapeutically equivalent, some transplant …
formulation, Advagraf®(Tac-OD). Although therapeutically equivalent, some transplant …
The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus
H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients
PT Loh, HX Lou, Y Zhao, YM Chin… - Transplantation …, 2008 - Elsevier
Calcineurin inhibitors (CNI) are metabolized by cytochrome-P4503A (CYP3A) enzymes and
extruded into the intestinal lumen by the drug efflux pump, P-glycoprotein (P-gp). The impact …
extruded into the intestinal lumen by the drug efflux pump, P-glycoprotein (P-gp). The impact …
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
S Contreras-Castillo, A Plaza, J Stojanova… - Frontiers in …, 2021 - frontiersin.org
Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
Influence of Combined CYP3A4 and CYP3A5 Single-Nucleotide Polymorphisms on Tacrolimus Exposure in Kidney Transplant Recipients: A Study According to the …
K Aouam, A Kolsi, E Kerkeni, N Ben Fredj… - …, 2015 - Taylor & Francis
Aim: The present study investigated in Tunisian renal transplant patients, genetic
polymorphisms of CYP3A4-392A> G and CYP3A5 6986A> G and their influence on …
polymorphisms of CYP3A4-392A> G and CYP3A5 6986A> G and their influence on …
Impact of CYP3A4* 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines
L Elens, A Capron, RHN van Schaik… - Therapeutic drug …, 2013 - journals.lww.com
Background: Tacrolimus (Tac) metabolism is mainly mediated by the cytochrome P450 3A
(CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying …
(CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying …
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
I Lunde, S Bremer, K Midtvedt, B Mohebi… - European journal of …, 2014 - Springer
Abstract Purpose Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by
CYP3A4 and CYP3A5. Several studies have demonstrated an association between the …
CYP3A4 and CYP3A5. Several studies have demonstrated an association between the …